Xbrane Biopharma AB (publ) (XBRANE.ST)
SEK 0.19
(-1.85%)
SEK 0.19
(-1.85%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 106.85 Million SEK | 112.61% |
| 2022 | 50.26 Million SEK | -76.69% |
| 2021 | 215.57 Million SEK | 0.0% |
| 2020 | - SEK | 0.0% |
| 2019 | - SEK | -100.0% |
| 2018 | 5.52 Million SEK | 80.26% |
| 2017 | 3.06 Million SEK | 22.75% |
| 2016 | 2.49 Million SEK | 1451.69% |
| 2015 | 160.91 Thousand SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| 2012 | - SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q3 | 212.96 Million SEK | -0.63% |
| 2024 Q2 | 214.32 Million SEK | 14.44% |
| 2024 Q1 | 187.28 Million SEK | 75.27% |
| 2023 Q4 | 106.85 Million SEK | -20.06% |
| 2023 Q1 | 53.73 Million SEK | 6.91% |
| 2023 FY | 106.85 Million SEK | 112.61% |
| 2023 Q3 | 133.66 Million SEK | 40.39% |
| 2023 Q2 | 95.2 Million SEK | 77.18% |
| 2022 FY | 50.26 Million SEK | -76.69% |
| 2022 Q3 | 1.00 SEK | -100.0% |
| 2022 Q2 | 213.27 Million SEK | 4.42% |
| 2022 Q1 | 204.24 Million SEK | 587.57% |
| 2022 Q4 | 50.26 Million SEK | 5025999900.0% |
| 2021 Q1 | 151.91 Million SEK | 395.65% |
| 2021 FY | 215.57 Million SEK | 0.0% |
| 2021 Q4 | -41.89 Million SEK | -158.88% |
| 2021 Q3 | 71.14 Million SEK | 325.19% |
| 2021 Q2 | -31.59 Million SEK | -120.8% |
| 2020 Q1 | - SEK | 0.0% |
| 2020 Q4 | -51.38 Million SEK | 0.0% |
| 2020 Q3 | - SEK | 0.0% |
| 2020 FY | - SEK | 0.0% |
| 2020 Q2 | - SEK | 0.0% |
| 2019 Q2 | 9.95 Million SEK | 11.7% |
| 2019 Q1 | 8.91 Million SEK | 61.3% |
| 2019 FY | - SEK | -100.0% |
| 2019 Q4 | - SEK | -100.0% |
| 2019 Q3 | 10.1 Million SEK | 1.48% |
| 2018 Q1 | 3.32 Million SEK | 8.32% |
| 2018 FY | 5.52 Million SEK | 80.26% |
| 2018 Q4 | 5.52 Million SEK | 108.41% |
| 2018 Q3 | 2.65 Million SEK | -36.65% |
| 2018 Q2 | 4.18 Million SEK | 26.05% |
| 2017 Q1 | 2.26 Million SEK | -9.42% |
| 2017 Q2 | 1.61 Million SEK | -28.44% |
| 2017 Q3 | 1.27 Million SEK | -21.44% |
| 2017 Q4 | 3.06 Million SEK | 141.08% |
| 2017 FY | 3.06 Million SEK | 22.75% |
| 2016 Q2 | 2.8 Million SEK | -6.93% |
| 2016 Q3 | 2.86 Million SEK | 2.29% |
| 2016 Q4 | 2.49 Million SEK | -12.98% |
| 2016 FY | 2.49 Million SEK | 1451.69% |
| 2016 Q1 | 3.01 Million SEK | 1772.89% |
| 2015 Q1 | - SEK | 100.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2015 Q4 | 160.91 Thousand SEK | 0.0% |
| 2015 FY | 160.91 Thousand SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| 2014 Q4 | -4813.00 SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| 2012 FY | - SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Active Biotech AB (publ) | -2500.00 SEK | 4274340.0% |
| Biovica International AB (publ) | 2.19 Million SEK | -4759.3% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| CombiGene AB (publ) | -1.79 Million SEK | 6039.744% |
| Cyxone AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 1.02 Million SEK | -10294.553% |
| Elicera Therapeutics AB (publ) | -446.98 Thousand SEK | 24005.894% |
| ExpreS2ion Biotech Holding AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | 3.15 Million SEK | -3292.254% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Mendus AB (publ) | - SEK | -Infinity% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| I-Tech AB | 4.28 Million SEK | -2396.636% |
| Intervacc AB (publ) | 10.48 Million SEK | -919.327% |
| Lipigon Pharmaceuticals AB (publ) | -1.62 Million SEK | 6671.71% |
| Magle Chemoswed Holding AB (publ) | 35.22 Million SEK | -203.318% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| OncoZenge AB (publ) | -862.99 Thousand SEK | 12481.938% |
| Sprint Bioscience AB (publ) | -7.13 Million SEK | 1597.422% |
| Lipum AB (publ) | - SEK | -Infinity% |
| Alligator Bioscience AB (publ) | 2.00 SEK | -5342799900.0% |
| Ziccum AB (publ) | -4.18 Million SEK | 2650.871% |
| BioArctic AB (publ) | - SEK | -Infinity% |
| Genovis AB (publ.) | 14.9 Million SEK | -616.914% |
| Camurus AB (publ) | 100.95 Million SEK | -5.845% |
| IRLAB Therapeutics AB (publ) | 1000.00 SEK | -10685500.0% |
| Bio-Works Technologies AB (publ) | 9.06 Million SEK | -1078.386% |
| Aptahem AB (publ) | - SEK | -Infinity% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Xspray Pharma AB (publ) | 43.78 Million SEK | -144.069% |
| Kancera AB (publ) | -1950.00 SEK | 5479894.872% |
| Saniona AB (publ) | 1.00 SEK | -10685599900.0% |
| Spago Nanomedical AB (publ) | 1.00 SEK | -10685599900.0% |
| AcouSort AB (publ) | 2.08 Million SEK | -5037.308% |
| Xintela AB (publ) | 398 Thousand SEK | -26748.241% |
| Abliva AB (publ) | - SEK | -Infinity% |
| Karolinska Development AB (publ) | - SEK | -Infinity% |
| Amniotics AB (publ) | 534 Thousand SEK | -19910.487% |
| 2cureX AB (publ) | -1000.00 SEK | 10685700.0% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 20.42 Million SEK | -423.086% |
| Hansa Biopharma AB (publ) | 9.79 Million SEK | -991.258% |
| Biosergen AB | -4.92 Million SEK | 2267.904% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | - SEK | -Infinity% |
| Corline Biomedical AB | -3.85 Million SEK | 2870.443% |
| NextCell Pharma AB | 545.23 Thousand SEK | -19498.083% |
| Nanologica AB (publ) | 2.97 Million SEK | -3494.215% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Egetis Therapeutics AB (publ) | 700 Thousand SEK | -15165.143% |
| BioInvent International AB (publ) | 11.84 Million SEK | -802.195% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | -321.14 Thousand SEK | 33373.443% |
| Alzinova AB (publ) | -3.27 Million SEK | 3359.794% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Oncopeptides AB (publ) | 2.42 Million SEK | -4306.433% |
| Pila Pharma AB (publ) | 1.00 SEK | -10685599900.0% |
| Guard Therapeutics International AB (publ) | -1486.00 SEK | 7190947.914% |
| Scandinavian ChemoTech AB (publ) | 4.03 Million SEK | -2548.884% |
| Simris Alg AB (publ) | 1.09 Million SEK | -9694.317% |
| Diamyd Medical AB (publ) | 24.05 Million SEK | -344.308% |